Patecibart
Based on 1 Customer Validation
Patecibart is a humanized immunoglobulin G4-kappa, anti-EDNRA monoclonal antibody. Patecibart is an endothelin receptor antagonist.
For research use only. We do not sell to patients.
- Purity: 97.77%
- CAS No.: 2642374-04-5
- Molecular Weight:145.269 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
EDNRA
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometry analysis of Raji cells with HY-P990089 at 20nM (Red). 20ng/mL of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) were added to block the binding of Fc of antibody to cells respectively. Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Unlabeled control - Unlabelled cells (Gray).
Chemical Information
-
CAS No. 2642374-04-5
-
Appearance Liquid
-
Molecular Weight 145.269 kDa
-
Color Colorless to light yellow
-
SMILES
[Patecibart]
-
Synonyms
Getagozumab; GMA-301
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)